Found 13 investors
Prof. Wojtek Wojakowski
Katowice, Slaskie, Poland
Professor of Cardiology. Head of Clinical Trials at CardioCube. Internationally recognized research impact (IF>410, H-index=24). European ...
Individual/Angel
Past Investments
CardioCube
Bill Stapleton
United States
Dr. Frederick Feit served as Board Member at Salus Telehealth. He also served as President and Board Member at Video Medicine. He is the Director of the Fellowship Training Program in Interventional Cardiology, and Associate Professor of Medicine at the NYU Langone School of Medicine, is recognized nationally and internationally for his scientific contributions and technical expertise. His pioneering research in collaboration with Dr. Rentrop, beginning in the Summer of 1981 was truly revolutionary in that he and his team injected thrombolytic agents (clot busting drugs) directly into totally obstructed coronary arteries of patients experiencing myocardial infarctions (heart attacks). These catheter-based, invasive, but non-surgical procedures were at the time considered to be too dangerous to perform during a myocardial infarction. Feit and his team not only proved that the procedure was safe, but that the clot-buster could restore blood flow and stop the progress of the heart attack. Subsequently, Dr. Feit has been Principal Investigator on numerous NIH-sponsored clinical trials involving patients with coronary artery disease those with diabetes mellitus and has served as Head of the Steering Committee of a Major International Trial.
Individual/Angel
Gonzalo Utrilla
United States
Mr. Paul Intlekofer founded and served as Chief Executive Officer at MMG Fusion. He serves as President, Chief Financial Officer and Managing Partner at SFP Capital. Mr. Paul Intlekofer is the President of SFP Capital. Previously he was the Executive Vice President and Chief Marketing Officer of Medifast. As EVP, Chief Marketing Officer of Medifast, Inc. (NYSE: Med) Paul managed and directed the largest business units and led sales, marketing, and customer service driving revenue increases from $75MM to $275MM in three years. He turned around an underperforming Direct Response division and call center, creating improved profits from $4MM to $22MM and led the growth of its Direct Sales division from $40MM to $160MM. Medifast was ranked as the #1 Small Cap U.S. Company in 2010 by Forbes, two years after Paul joined the Company. In 2002 Paul joined Nutrition 21, a biotechnology company, to help it secure financing for R&D and to commercialize its technology. When the clinical trials failed, Paul was promoted to CEO, transformed the business and grew revenues from $10MM to $46MM in three years. The company was recognized by Nutrition Business Journal in 2006 for Acquisition of the Year, and in 2007 for Fastest Growing Small Cap Company.
Individual/Angel
Greg Fant
United States
Mr. Joshua Adler is a Co-Founder and serves as Principal, Managing Partner at LaKritz Adler Real Estate Investments. He is the Founding Investor & serves as Board Member at MegaBots. He is the Founder of Sourcewater and also serves as its President, Chief Executive Officer and Board Member. Joshua A. At LaKritz Adler Development, he manages the firm's asset acquisition and disposition activities, including its investment valuation and analysis functions. Mr. Adler is a member of the Urban Land Institute (ULI), International Council of Shopping Centers (ICSC) and the Pension Real Estate Association (PREA).Previously, Mr. Adler served as Chief Speechwriter for the United States Treasury Department under United States Treasury Secretaries Paul O'Neill and John Snow. At Treasury, Mr. Adler played a senior role in designing, promoting and explaining U.S. economic policy. From 2002 to 2003, Mr. Adler drafted every major public statement of the United States Treasury Secretary, including matters of tax policy, economic stimulus, corporate responsibility, foreign investment and international development. In 1996, Mr. Adler co-founded iLife Systems, Inc., a wireless biosensor technology company based in Dallas, Texas, where he managed worldwide clinical trials and regulatory approvals, raised several rounds of venture capital, and executed technology licensing agreements on three continents. Earlier, Mr. Adler co-founded Amour.com, a nationwide scholastic online matchmaking company, where as CEO he expanded the company's customer base to more than 500,000 users in 50 states and sold the company to a French firm in the first international sale of an Internet domain. Mr. Adler holds a B.A. in Economics from Yale University, with a concentration in Chinese Studies. At Yale, he emceed the Whiffenpoofs, America's oldest and best-known collegiate a cappella group. Mr. Adler now serves as a Trustee of the Yale Whiffenpoof Alumni, and he is active in the Socrates Society of the Aspen Institute. Mr. Adler's essays and commentaries have appeared in The New York Times, The Washington Post, The Wall Street Journal, The Economist, The Dallas Morning News, Wired and Fast Company. Joshua Adler is a Sloan Fellow for Innovation and Global Leadership at the Massachusetts Institute of Technology.
Individual/Angel
Gund Investment
United States
Mr. Gerard Ryan serves as Angel Investor. Mr. Ryan served as Chairman at Longboat Clinical. He is an entrepreneur and investor with diverse interests in medical and technology start-ups. Prior to Longboat Clinical, Gerard founded two companies (Firecrest Clinical and Ryan Group Holdings) and exited successfully by way of trade sales to major listed PLC companies. Gerard became CEO of Firecrest Clinical as it pivoted from a failing e-learning company into a pioneer of web-based training for clinical trial investigators. He also served as Chairman of Firecrest Clinical until its acquisition by ICON plc in 2011. Gerard is a Chartered Director (IOD) and a Pharmacist, registered in Ireland. He qualified in Pharmacy at Trinity College Dublin and obtained a Postgraduate Diploma in Clinical Trials at London School of Hygiene and Tropical Medicine.
Individual/Angel
Incendium Capital
United States
Dr. Jean-Luc Neptune serves as Partner at Blueprint Health. He Founded & served as General Manager at Athletik Sports Medicine. He Co-Founded and served as Program Manager, Accelerator Leader & Executive Director at Blueprint Health where he still serves as Partner. He serves as Advisor at Proteus Motion. Dr. Neptune is an Angel Investor at Jean-Luc Neptune. He serves as Advisor at MedPilot. He serves as Advisor at Cecelia Health. Prior to his current role he was Senior Vice President at Health 2.0 and Director of the Health 2.0 Developer Challenge program. He is a Co-Founder of two digital health startups including Healogica, an online clinical trials matching platform, and expert consensus, a virtual second opinion service. JL is an investor in a number of web-based ventures and serves as a formal and informal advisor to more than a dozen digital health start-ups.
Individual/Angel
INEO Beteiligungs
United States
Dr. Dimitri Karmpaliotis serves as Member of the Scientific Advisory Board & Board Member at Traverse Vascular. He is also an Angel Investor. He is a member of the Center for Interventional Vascular Therapy at Columbia University Medical Center. He specializes in advanced, complex coronary intervention. He brings experience in percutaneous coronary interventions and will direct the new Chronic Total Occlusions, Complex, and High-Risk Angioplasty Program at CIVT. Before coming to Columbia University, he was instrumental in building an interventional cardiology program at Piedmont Heart Center in Atlanta, Georgia. He has served as principal investigator on more than 50 clinical trials, with a special interest in the development of techniques for treating chronic total occlusions in coronary arteries. He graduated from the University of Athens School of Health Sciences in 1996 and trained at the prestigious Beth Israel Deaconess Medical Center at Harvard Medical School.
Individual/Angel
Meissa Capital
United States
Mr. Robert Butchofsky co-founded & served as Secretary, Board Member, President and Chief Executive Officer at Mati Therapeutics. Currently the Chief Executive Officer of Mati Therapeutics, Bob Butchofsky is the former President and CEO of QLT Inc. He served as interim CEO from September of 2005, becoming CEO and a Board member in February 2006 and continuing in that capacity until August 2012. During his tenure as CEO, Mr. Butchofsky modified the company's strategy and focused the company in ophthalmology resulting in the divestment of non-core assets generic dermatology business (2006), Aczone (2008), Atrigel (2008), the corporate headquarters building and land (2008) and Eligard (2009). Part of the ocular focused strategy resulted in the acquisition of innovative new technologies including a synthetic retinoid program from Retinagenix for inherited retinal diseases and the punctal plug drug delivery technology from ForSight Labs. Mr Butchofsky was also successful in obtaining US commercial rights for Visudyne from Novartis and launched a US commercial team to promote the brand to ophthalmologists. Mr. Butchofsky joined QLT in 1998 as Associate Director, Ocular Marketing and was appointed Vice President, Marketing and Sales Planning in September 2001. Mr. Butchofsky was promoted to Senior Vice President, Marketing and Sales Planning in early 2005, responsible for QLT's marketing of the pharmaceutical products, Visudyne® and Eligard®, including managing significant corporate partnerships, as well as corporate strategy development and investor relations activities. From June 1990 to August 1998, Mr. Butchofsky was employed at Allergan Inc., a pharmaceutical company, where he built an extensive background with ocular pharmaceutical products and Botox®, including sales, health economics, worldwide medical marketing, and product management. Prior to joining Allergan Inc., Mr. Butchofsky spent several years managing clinical trials at the Institute for Biological Research and Development. Mr. Butchofsky also serves as Chairman of the Board of Superna Life Sciences Inc., a privately-held pharmaceutical company located in Vancouver, British Columbia. He is also Chairman of the Board of CDRD Ventures the commercial arm of the Center for Drug Research and Development. Mr. Butchofsky has a Bachelor of Arts degree in Biology from the University of Texas and a Masters of Business Administration from Pepperdine University.
Individual/Angel
Mochio Umeda
United States
Mr. William Stilley serves as Chief Executive Officer, President and Board Member at Adial Pharmaceuticals. He also was a Co-Founder of Purnovate. He is an Angel Investor. Prior to joining ADial Pharmaceuticals, LLC, he was the Vice President, Business Development & Strategic Projects at PGxHealth, LLC, a division of Clinical Data, Inc. (NASDQ CLDA). At PGxHealth, he worked on licensing and M&A transactions and was involved in the management of Phase III clinical trials, production of Viibryd® for an initial commercial launch of the product and sourcing drug product and drug substance for Stedivaze's Phase III clinical trials. Previously, he was the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development and all financing activity until Adenosine Therapeutics was acquired by PGxHealth in August 2008. He also worked closely with the CEO on all of the company's major transactions. He has advised both public and private companies on financing and M&A transactions have been the interim CFO of a public company and the COO and CFO of a number of private companies. Before entering the business community, he served as Captain in the U.S. Marine Corps. He has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He currently guest lectures at the Darden School of Business in two courses on the management of life science companies and serves on the Board of Virginia BIO, the statewide biotechnology organization.
Individual/Angel
Nelson Garrison
United States
Mr. Shahram Seyedin-Noor is the Founder and serves as General Partner at Civilization Ventures. He is also a Co-Founder at Rgenix and previously served as an Advisor. He also serves as Board Member at Foresight Diagnostics. He was previously its Executive Chairman and Chief Business Officer. Prior to Rgenix, Mr. Seyedin-Noor was a founding executive at NextBio, a pioneer in genomics data analysis and personalized medicine. NextBio was acquired by Illumina in 2013 (NASDAQ: ILMN). Mr. Seyedin-Noor helped grow NextBio into a profitable leader in the life sciences with millions in revenues from top-tier customers such as Merck, Celgene, J&J, Regeneron, Pfizer and nearly every other major biotech/pharma company. He is also an angel investor in various innovative healthcare startups, including Avantome (acq. by Illumina), Bina Technologies (acq. by Roche), Counsyl and Omada Health, among others. Prior to founding Civilization Ventures, Shahram was an entrepreneur and angel investor. Shahram is a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class therapeutics for cancer, now in Phase 1 clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics big data analytics pioneer acquired by Illumina in 2013. Shahram is also a seed investor in category-defining startups such as Omada Health and Counsyl. Shahram began his career in Silicon Valley as startup counsel at Wilson Sonsini Goodrich & Rosati, and later as a high tech investment banker at Goldman Sachs. Shahram earned his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and obtained a BA in Economics from Pomona College.
Individual/Angel
Orange Grove Bio
United States
Orange Grove Bio is a venture capital firm headquartered in New York, New York. The firm is a preclinical drug investment and development platform that partners with universities and entrepreneurs to build biotech companies with a particular interest in oncology, inflammatory, and autoimmune disease treatments and focuses on driving down the cost of drug discovery and advancing therapies into clinical trials.
Venture Capital
Percy Capital
United States
Mr. David Marson is an Angel Investor. He served as Chief Financial Officer & Board Member at Accentus Medical. He has an extensive track record in the financial and operational management of small- and medium-sized technology based businesses, having worked at AEA Technology plc where he held various senior roles as a divisional General Manager and as divisional Finance Director. In this period he was instrumental in the spin-out of a number of successful ventures, including Forensic Alliance Ltd, now a part of LGC Forensics, and Synexus Ltd, the clinical trials patient recruitment organization. He also held a number of Non-Executive Directorships, including Benitec Ltd, a bio-technology start-up company now listed on ASX. Since 2006 he has provided finance director and other financial management services to listed and unlisted companies in various high technology sectors. He is also Finance Director and Company Secretary of AFC Energy Plc, an AIM listed developer of hydrogen fuel cell systems.
Individual/Angel
Timothy Howes
United States
Alan Auerbach serves as Chief Executive Officer, President and Chairman at Puma Biotechnology. Prior to founding Puma, Mr. Auerbach Founded Cougar Biotechnology and served as its Chief Executive Officer, President and a Board Member. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the European Union in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by the company. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach currently serves as a director of Radius Health, a pharmaceutical company focused on developing new drugs for osteoporosis and women's health. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. He is also an Angel Investor.
Individual/Angel
Found 13 results